RxDoctor Payments Data

Monica Goetz

Family · Bismarck, NDNPI 1245873207

Payments from drug & device makers

What this record shows

14 manufacturers reported payments, led by Abbott at 27.0% of the total. Reporting peaked in 2024 at $2,462 and has fallen 72.6% since, to $674 in 2025. Among family clinicians in ND with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,830in general payments, 2019–2025

Across 151 payments — averaging $51.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Si-bone, Inc.$1K
  • Boston Scientific$1K
  • Medtronic$929
  • Nevro Corp.$912
  • AbbVie$902
  • plus $435 from 8 others

What the payments were for

  • Travel & lodging$3,63146%
  • Food & beverage$4,19954%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,830 in reported general payments places this provider in the 95th percentile of 496 family providers in North Dakota.

See all family providers in North Dakota

Medicare billing

Part B allowed, 2024
$6,506
Medicare patients
96
Services billed
117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QuliptaAtogepant11$12,087
Pregabalin40$962
Gabapentin11$303

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta$902$12,08711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 496 family providers in North Dakota.

Other family in Bismarck

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →